



Joe Manchin III
Governor

STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
Bureau for Medical Services
Office of Pharmacy Services
350 Capitol Street - Room 251
Charleston, West Virginia 25301-3706
Phone: (304) 558-1700 - Fax: (304) 558-1542

Martha Yeager Walker
Secretary

Pharmaceutical and Therapeutics (P&T) Committee
April 29, 2009
Diamond Building
Rooms B10 & B11
Charleston, West Virginia

MINUTES

Members Present:

David Avery, M.D.
James D. Bartsch, R.Ph.
Teresa Dunsworth, PharmD
Barbara Koster, N.P.
Harriet Nottingham, R.Ph.
Michael Grome, PA-C
Ahmed Faheem, M.D.
Rodney L. Fink, D.O.
Teresa Frazer, M.D., FAAP
Jeffrey V. Ashley, M.D.
Robert Stanton, PharmD
Gene Makela, PharmD

Members Not Present:

Steven R. Matulis, M.D.
Scott Brown, R.Ph.

DHHR/BMS Staff Present:

Peggy King, R.Ph., Pharmacy Director
Gail Goodnight, R.Ph. Rebate Coordinator
Vicki Cunningham, R.Ph., DUR Coordinator
William Hopkins, Pharmacy Operations
Manager
Lynda Edwards, Secretary

Contract Staff/GHS Staff Present:

Laureen Biczak, D.O.
Tim Clifford, M.D.
Shelagh Harvard

Other Contract Staff/State Staff Present:

Stephen Small, R.Ph., M.S., Rational Drug
Therapy Program
Eric Sears, R.Ph., Unisys

I. Call to Order

Dr. David Avery, M.D., Chairperson, called the meeting to order at 2:08 p.m.

II. Housekeeping

All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

III. Approval of February 25, 2009 Meeting Minutes

Chairman Avery asked for approval of the minutes from the last meeting. A motion was made and seconded and the motion carried to approve the minutes as submitted.

IV. Public Comment Period

Vanessa Land, GSK, spoke in favor of Lovaza.

Robert Yee, Abbott, spoke in favor of Trilipix.

Barbara Tolbert, Takeda, spoke in favor of Kapidex.

V. Executive Session

The Committee adjourned to Executive Session at 2:20 and resumed open session at 3:15.

VI. Old Business

Dr. Biczak reviewed the PDL Compliance Report; overall compliance for Q1-2009 is 95.6%.

Dr. Biczak reviewed the Generic Utilization Report; generic utilization for Q1-2009 was 71.1%.

VII. New Business

Dr. Avery called for review of the Therapeutic Classes.

VIII. Therapeutic Class Reviews

A. Cough & Cold

GHS recommended that the following list be approved. A motion was made to amend the recommendation to include an additional codeine containing option on the list that did not also carry promethazine, at least for children. The motion was seconded, votes were taken and the motion carried. A motion was made to accept the amended recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ANTIHISTAMINES, 1ST GENERATION	
chlorpheniramine maleate clemastine cyproheptadine diphenhydramine promethazine	brompheniramine maleate brompheniramine tannate BROVEX (brompheniramine tannate) carbinoxamine maleate LODRANE (brompheniramine maleate and tannate) LOHIST (brompheniramine maleate) PALGIC (carbinoxamine maleate) TANACOF (brompheniramine tannate) TANAHIST-PD (chlorpheniramine tannate)
ANTITUSSIVE-ANTIHISTAMINE COMBINATIONS	
codeine/promethazine dextromethorphan HBR/promethazine	
ANTIHISTAMINE-ANTITUSSIVE-DECONGESTANT COMBINATIONS	
brompheniramine/dextromethorphan HBR/pseudoephedrine chlorpheniramine/dextromethorphan/ pseudoephedrine promethazine/codeine/phenylephrine	
ANTITUSSIVE-DECONGESTANT COMBINATIONS	
	MUCINEX-D (guaifenesin/pseudoephedrine)
DECONGESTANTS	
phenylephrine pseudoephedrine	NASOP (phenylephrine)
ANTITUSSIVES/EXPECTORANTS	
benzonatate guaifenesin guaifenesin/dextromethorphan	MUCINEX (guaifenesin) MUCINEX-DM (guaifenesin/dextromethorphan) TESSALON (benzonatate)
DECONGESTANT-ANTIHISTAMINE-ANTICHOLINERGIC COMBINATIONS	
phenylephrine/chlorpheniramine/ scopolamine	DURAHIST (pseudoephedrine/chlorpheniramine/ methscopolamine) EXTENDRYL CHW /JR TAB (phenylephrine/chlorpheniramine/ scopolamine) EXTENDRYL SOL (phenylephrine/dexchlorpheniramine/

PREFERRED AGENTS	NON-PREFERRED AGENTS
	methscopolamine) NOHIST-PLUS (phenylephrine/ chlorpheniramine/methscopolamine) phenylephrine/chlorpheniramine/ methscopolamine pseudoephedrine/chlorpheniramine/ methscopolamine phenylephrine/dexchlorpheniramine/ methscopolamine RE-DRYLEX JR (phenylephrine/ chlorpheniramine/scopolamine) RE-DRYLEX SYRUP (phenylephrine/dexchlorpheniramine/ methscopolamine) SCOPOHIST (pseudoephedrine/ chlorpheniramine/methscopolamine)
DECONGESTANT-ANTI-HISTAMINE COMBINATIONS	
phenylephrine HCL/chlorpheniramine maleate phenylephrine HCL/phenyltoloxamine/ chlorpheniramine phenylephrine HCL/promethazine phenylephrine HCL/pyrilamine maleate/chlorpheniramine phenylephrine tannate/diphenhydramine tannate phenylephrine tannate/pyrilamine tannate/chlorpheniramine suspension pseudoephedrine/brompheniramine pseudoephedrine/chlorpheniramine	BROVEX-D (phenylephrine/ brompheniramine) CHLOR-TAN SUSP (phenylephrine tannate/pyrilamine tannate/ chlorpheniramine) DURATUSS DA (pseudoephedrine/chlorpheniramine) DYTAN-D CHW/SUSP (phenylephrine tannate/diphenhydramine tannate) LODRANE 12D/24D//D (pseudoephedrine/brompheniramine) LOHIST 12D/PD (pseudoephedrine/brompheniramine) LOHIST-D (pseudoephedrine/chlorpheniramine) NALEX-A LIQUID/SUSPENSION (phenylephrine/phenyltoloxamine/ chlorpheniramine) phenylephrine/brompheniramine phenylephrine tannate/chlorpheniramine tannate POLY HIST FORTE/PD (phenylephrine/ pyrilamine/chlorpheniramine) RONDEC (phenylephrine/chlorpheniramine) RU-HIST FORTE (phenylephrine/pyrilamine/ chlorpheniramine) RYNATAN (phenylephrine/chlorpheniramine) SUDAL 12 (pseudoephedrine/chlorpheniramine) TANNATE PED SUSP (phenylephrine/chlorpheniramine)

B. Prenatal Vitamins

GHS recommended that the following list be approved. A motion was made to accept the recommendations of GHS. The motion was seconded, votes were taken and the motion carried.

PREFERRED AGENTS	NON-PREFERRED AGENTS
prenatal vitamin 27 w/calcium/ferrous fumarate/folic acid prenatal vitamins 28 w/calcium/iron ps complex/folic acid	CARENATAL DHA CITRANATAL DHA COMBI RX
prenatal vitamins/ferrous fumarate/docusate/folic acid prenatal vitamins/ferrous fumarate/folic acid	FOLBECAL DUET/DUET DHA
prenatal vitamins/ferrous fumarate/folic acid/selenium	FOLTABS PLUS DHA
prenatal vitamins/iron, carbonyl/folic acid	NATACHEW
prenatal vitamins/iron polysaccharides complex/folic acid	NATAFORT NATELLE PLUS W/DHA
prenatal vitamins comb 10/ferrous fumarate/folic acid	NEEVO
prenatal vitamin no. 15/iron, carbonyl/folic acid/docusate sod	NOVANATAL OB-NATAL ONE
prenatal vitamin no. 16/iron, carbonyl/folic acid/docusate sod	OPTINATE PRECARE/PRECARE PREMIER
prenatal vitamin no. 17/iron, carbonyl/folic acid/docusate sod	PREMESIS prenatal vitamins/ferrous bis-glycinate chelate/folic acid
prenatal vitamin no. 18/iron, carbonyl/folic acid/docusate sod	prenatal vitamins/iron, carbonyl/omega-3/FA/fat combo no. 1
prenatal vitamin w-o calcium/ferrous fumarate/folic acid prenatal vitamins w-o vit A/iron, carbonyl/folic acid	prenatal vitamins comb no. 20/iron bisglycinate/folic acid/DHA
	prenatal vitamins no. 22/iron, carbonyl/FA/docusate/DHA prenatal vitamins w-CA, FE, FA (<1 mg)
	prenatal vitamins w-o calcium/iron ps complex/FA prenatal vitamins w-o CA no. 5/ferrous fumarate/folic acid
	prenatal vitamins CMB w-o CA no. 2
	prenatal vitamins w-o calcium no. 9/iron/folic acid PRENATE DHA/PRENATE ELITE
	PRENAVITE PRENEXA
	PRIMACARE RENATE/RENATE DHA
	SELECT-OB TANDEM DHA/TANDEM OB

Single Drug Recommendations

A. Acanya

GHS recommended that Acanya be made a non-preferred drug in the Acne Agents, Topical, Combination category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

B. Apriso

GHS recommended that Apriso be made a non-preferred drug in the Ulcerative Colitis Agents, Oral category. A motion was made to make Apriso a preferred medication. The motion was seconded, votes were taken and the motion carried.

C. Banzel

GHS recommended that Banzel be made a non-preferred drug in the Anticonvulsants, Adjuvants category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

D. Kapidex

GHS recommended that Kapidex be made a non-preferred drug in the Proton Pump Inhibitors category. Chairman Avery commented that Nexium and Prevacid are currently under contract and that this category could change with emerging generics. Dr. Clifford commented that this vote could be viewed as an initial decision, and that the Committee can revisit the issue at a later date. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

E. Rapaflo

GHS recommended that Rapaflo be made a non-preferred drug in the BPH Agents, Alpha Blockers category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

F. Trilipix

GHS recommended that Trilipix be made a preferred drug in the Lipotropics, Other (non-statins), Fibric Acid Derivatives category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

IX. Other Business

A. Lovaza

GHS recommended that Lovaza be made a preferred drug in the Lipotropics, Other Non-statins, Fatty Acids class, and that the DUR Committee consider the listed PDL criteria remain in effect. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

B. Conflict of Interest

Dr. Faheem inquired about conflict of interest rules. Ms. King explained that the paperwork will be sent out this summer, including a conflict of interest form. The bylaws require that members sign the form each year.

C. Swine Flu

Dr. Frazer asked about Tamiflu availability. Chairman Avery noted that it is still available in many locations around the State. He further noted that the CDC recommends that only those patients with documented exposure be given medications. He directed all members to refer any media requests to Public Health officials.

D. HFA Inhalers

Dr. Frazer inquired whether the changeover to HFA inhalers from the older aerosol has had an impact on the budget. Ms. King noted that since the inhalers are one of the top 25 drugs utilized by Medicaid patients, the switch has had an impact. GHS will update the Committee during the next session.

X. Next Meeting Date

The next meeting of the P&T Committee will be held on October 28, 2009.

XI. Adjournment

A motion was made, was seconded, votes were taken and the motion carried to adjourn the meeting of the Pharmaceutical and Therapeutics Committee at 3:51 p.m.